🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings


Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.


If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.


If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies


Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

Trader's Diary

Economic calendar

Jun
2025
Definition of terms:
Earnings
IPOs
Splits
Week 23

Novo Nordisk is positive about their weight loss pills

Date: 26.6.2023

Many times, I have read that obesity is one of the deadliest diseases. To be frank, not obesity itself, but the diseases it can lead to can be fatal. And not only that, in the US, obesity is second only to smoking as the most preventable cause of deaths. It is no wonder that people are battling it, if I just look at the way of life we are living. Let’s say you are at work, sitting at the table for the whole day. You come home; you sit on the couch. We eat a lot of processed foods and voila, additional kilograms are here. One of the ways to fight it is with good diet and working out, however, in the past years also pharmaceutical companies searched for a way to help it. And they have found a solution. At least partly.

Article on Investing said that Novo Nordisk announced that a late-stage trial demonstrated the efficacy of a high-dose oral version of its drug semaglutide in helping overweight or obese adults lose 15% of their body weight. This aligns with recent findings from other experimental obesity pills. The Danish company intends to seek regulatory approval in the United States and Europe for the high-dose pill later this year. However, the timing for its market launch has yet to be determined. Novo Nordisk has faced challenges in meeting the surging demand for its semaglutide products for obesity and diabetes treatment due to supply issues. The high-dose pill is part of a new class of drugs that activate hormones to regulate blood sugar, slow stomach emptying, and reduce appetite. The obesity treatment market is estimated to reach 100 billion USD by the end of the decade, driving interest from researchers and investors. Novo Nordisk aims to increase production to address the demand. The recent trial involved 667 overweight and obese adults, and the high-dose oral semaglutide resulted in an average weight loss of 15.1% after 68 weeks when combined with diet and physical activity. Gastrointestinal side effects were reported, including mild-to-moderate nausea, constipation, diarrhoea, vomiting, and altered skin sensation.

In my opinion, amazing news for companies developing such pills. Especially the fact that this sector is expected to reach 100 billion USD by the end of the decade. I was very satisfied with what I read, so I decided to check closer the movement of their stocks.

Novo Nordisk had their stocks on the market since 1981, when the price for a stock was only 1,60 USD. Since then, company managed to evolve their stock to their current price, which is also very near to the all-time high, at 159 USD per stock. * Unbelievable growth and performance. It is a clear signal that they are doing something right. Not only that, but company also had 4 stock splits in their past, meaning that I can expect a new one soon, since the price is that high. However, this can’t be taken for granted and should not be relied on. Despite being on the one of the highest points, I have decided to enter the trade as soon as the market opens. It is also important to mention that I can pick stocks from US stock exchange, or Danish stock exchange, because the company is Danish. However, I will go with the first option.

Picture1

Movement of Novo Nordisk stocks in the last five years. (Source: Investing) *

* Past performance is no guarantee of future results.

Date: 26.2.2025
Super Micro Averts the Threat of Delisting and Rises Sharply

After analyzing the quarterly results of Super Micro Computer Inc. (NASDAQ: SMCI), I noticed a sharp increase in the price of their shares. In extended trading, they rose by about 22% after the company filed its late financial statements on time to meet the Nasdaq exchange's requirements to remain in the index. The move removed the threat of delisting that hung over the firm due to financial reporting issues and the loss of an auditor in 2023. At the same time, Super Micro announced that the new BDO auditor confirmed the compliance of the results with GAAP accounting principles, which managed to stabilize the situation. What awaits us next?

Date: 19.2.2025
Intel and Speculation About a Possible Company Split

Today, I noticed that Intel's stock has risen by nearly 50% from its February low, clearly indicating that the price is reacting to ongoing speculation about a potential company split.* Intel has been struggling with the loss of its technological edge and market share, with its performance lagging behind competitors like Nvidia, which dominates the AI chip segment. Ongoing negotiations between TSMC, Broadcom, and the Silver Lake investment group suggest that Intel's leadership is actively exploring ways to regain its market position and restore investor confidence.

Date: 12.2.2025
Alibaba and Apple Forge AI Partnership in China

This morning, I noticed a sharp increase in Alibaba shares – almost 8%1 since last week. The stock thus continues the bullish trend that we last saw in September last year.* I immediately started to find out what was behind it, and I came across an interesting piece of news. Apple is reportedly working with Alibaba to develop AI features for iPhones in China. This news immediately caught my attention, so I started looking for ways to benefit from it.

Date: 5.2.2025
AMD Slips After Earnings Report

For us investors following the semiconductor sector, today was very significant. AMD announced its results for the fourth quarter of 2024, beating expectations in terms of both sales and profit. Nevertheless, the shares fell by more than 9% after the end of regular trading hours.* This decline subsequently raised questions that I also dealt with. Is this an overreaction of the market, or is it a legitimate warning sign?

Date: 29.1.2025
ASML Exceeds Expectations: A Buying Opportunity?

Today's trading day was very interesting for me as I focused on the results of ASML, a leading player in chip manufacturing equipment, which published its results for the fourth quarter. ASML reported orders worth €7.09 billion, well above expectations. This order intake is a significant indicator that the demand for advanced equipment, driven by the growth of the AI field, remains strong.

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.